Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 79

1.

Non-Opioid Neurotransmitter Systems that Contribute to the Opioid Withdrawal Syndrome: A Review of Preclinical and Human Evidence.

Dunn KE, Huhn AS, Bergeria CL, Gipson CD, Weerts EM.

J Pharmacol Exp Ther. 2019 Aug 7. pii: jpet.119.258004. doi: 10.1124/jpet.119.258004. [Epub ahead of print]

2.

Drug Legalization and Decriminalization Beliefs Among Substance-using and Nonusing Individuals.

Hammond AS, Dunn KE, Strain EC.

J Addict Med. 2019 Aug 2. doi: 10.1097/ADM.0000000000000542. [Epub ahead of print]

PMID:
31385846
3.

Buprenorphine in the United States: Motives for abuse, misuse, and diversion.

Chilcoat HD, Amick HR, Sherwood MR, Dunn KE.

J Subst Abuse Treat. 2019 Sep;104:148-157. doi: 10.1016/j.jsat.2019.07.005. Epub 2019 Jul 12.

PMID:
31370979
4.

The relationship between pupil diameter and other measures of opioid withdrawal during naloxone precipitated withdrawal.

Bergeria CL, Huhn AS, Tompkins DA, Bigelow GE, Strain EC, Dunn KE.

Drug Alcohol Depend. 2019 Sep 1;202:111-114. doi: 10.1016/j.drugalcdep.2019.05.010. Epub 2019 Jul 16.

PMID:
31336328
5.

Promoting a comprehensive understanding of the opioid epidemic.

Dunn KE.

Int Rev Psychiatry. 2018 Oct;30(5):89-90. doi: 10.1080/09540261.2018.1530168. No abstract available.

PMID:
31282809
6.

Review: Sex-Based Differences in Treatment Outcomes for Persons With Opioid Use Disorder.

Huhn AS, Berry MS, Dunn KE.

Am J Addict. 2019 Jul;28(4):246-261. doi: 10.1111/ajad.12921. Epub 2019 May 26. Review.

PMID:
31131505
7.

Randomized comparison of two web-based interventions on immediate and 30-day opioid overdose knowledge in three unique risk groups.

Bergeria CL, Huhn AS, Dunn KE.

Prev Med. 2019 May 10. pii: S0091-7435(19)30174-4. doi: 10.1016/j.ypmed.2019.05.006. [Epub ahead of print]

PMID:
31078564
8.

Individuals with Chronic Pain Who Misuse Prescription Opioids Report Sex-Based Differences in Pain and Opioid Withdrawal.

Huhn AS, Tompkins DA, Campbell CM, Dunn KE.

Pain Med. 2019 Jan 25. doi: 10.1093/pm/pny295. [Epub ahead of print]

PMID:
30690594
9.

Recovery Goals and Long-term Treatment Preference in Persons Who Engage in Nonmedical Opioid Use.

Hay KR, Huhn AS, Tompkins DA, Dunn KE.

J Addict Med. 2019 Jul/Aug;13(4):300-305. doi: 10.1097/ADM.0000000000000498.

PMID:
30633045
10.

Systematic review of sex-based differences in opioid-based effects.

Huhn AS, Berry MS, Dunn KE.

Int Rev Psychiatry. 2018 Oct;30(5):107-116. doi: 10.1080/09540261.2018.1514295. Epub 2018 Dec 6.

PMID:
30522374
11.

Gabapentin Enacarbil Extended-Release for Alcohol Use Disorder: A Randomized, Double-Blind, Placebo-Controlled, Multisite Trial Assessing Efficacy and Safety.

Falk DE, Ryan ML, Fertig JB, Devine EG, Cruz R, Brown ES, Burns H, Salloum IM, Newport DJ, Mendelson J, Galloway G, Kampman K, Brooks C, Green AI, Brunette MF, Rosenthal RN, Dunn KE, Strain EC, Ray L, Shoptaw S, Ait-Daoud Tiouririne N, Gunderson EW, Ransom J, Scott C, Leggio L, Caras S, Mason BJ, Litten RZ; National Institute on Alcohol Abuse and Alcoholism Clinical Investigations Group (NCIG) Study Group.

Alcohol Clin Exp Res. 2019 Jan;43(1):158-169. doi: 10.1111/acer.13917. Epub 2018 Dec 9.

PMID:
30403402
12.

A hidden aspect of the U.S. opioid crisis: Rise in first-time treatment admissions for older adults with opioid use disorder.

Huhn AS, Strain EC, Tompkins DA, Dunn KE.

Drug Alcohol Depend. 2018 Dec 1;193:142-147. doi: 10.1016/j.drugalcdep.2018.10.002. Epub 2018 Oct 18.

PMID:
30384321
13.

Prefrontal cortex response to drug cues, craving, and current depressive symptoms are associated with treatment outcomes in methadone-maintained patients.

Huhn AS, Sweeney MM, Brooner RK, Kidorf MS, Tompkins DA, Ayaz H, Dunn KE.

Neuropsychopharmacology. 2019 Mar;44(4):826-833. doi: 10.1038/s41386-018-0252-0. Epub 2018 Oct 30.

PMID:
30375498
14.

Preliminary evidence of different and clinically meaningful opioid withdrawal phenotypes.

Dunn KE, Weerts EM, Huhn AS, Schroeder JR, Tompkins DA, Bigelow GE, Strain EC.

Addict Biol. 2018 Oct 8. doi: 10.1111/adb.12680. [Epub ahead of print]

PMID:
30295400
15.

Towards a Bioelectronic Computer: A Theoretical Study of a Multi-Layer Biomolecular Computing System That Can Process Electronic Inputs.

Dunn KE, Trefzer MA, Johnson S, Tyrrell AM.

Int J Mol Sci. 2018 Sep 4;19(9). pii: E2620. doi: 10.3390/ijms19092620.

16.

Pain as a predictor and consequence of tobacco abstinence effects amongst African American smokers.

Bello MS, McBeth JF, Ditre JW, Kirkpatrick MG, Ray LA, Dunn KE, Leventhal AM.

J Abnorm Psychol. 2018 Oct;127(7):683-694. doi: 10.1037/abn0000367. Epub 2018 Aug 2.

PMID:
30070540
17.

Characterizing Surface-Immobilized DNA Structures and Devices Using a Quartz Crystal Microbalance with Dissipation Monitoring (QCM-D).

Dunn KE, Trefzer MA, Johnson S, Tyrrell AM.

Methods Mol Biol. 2018;1811:101-114. doi: 10.1007/978-1-4939-8582-1_7.

PMID:
29926448
18.

Dimensions and Global Twist of Single-Layer DNA Origami Measured by Small-Angle X-ray Scattering.

Baker MAB, Tuckwell AJ, Berengut JF, Bath J, Benn F, Duff AP, Whitten AE, Dunn KE, Hynson RM, Turberfield AJ, Lee LK.

ACS Nano. 2018 Jun 26;12(6):5791-5799. doi: 10.1021/acsnano.8b01669. Epub 2018 Jun 4.

PMID:
29812934
19.

Naloxone formulation for overdose reversal preference among patients receiving opioids for pain management.

Dunn KE, Barrett FS, Bigelow GE.

Addict Behav. 2018 Nov;86:56-60. doi: 10.1016/j.addbeh.2018.03.011. Epub 2018 Mar 28.

PMID:
29625751
20.

Opioid Overdose Education for Individuals Prescribed Opioids for Pain Management: Randomized Comparison of Two Computer-Based Interventions.

Huhn AS, Garcia-Romeu AP, Dunn KE.

Front Psychiatry. 2018 Feb 12;9:34. doi: 10.3389/fpsyt.2018.00034. eCollection 2018.

21.

Tramadol Extended-Release and Opioid Withdrawal Management-Legal Implications-Reply.

Dunn KE, Tompkins DA, Strain EC.

JAMA Psychiatry. 2018 Feb 1;75(2):215. doi: 10.1001/jamapsychiatry.2017.3827. No abstract available.

PMID:
29282473
22.

Effectiveness, Implementation and Real-World Experience with Extended-Release Naltrexone (XR-NTX): A Special Issue of JSAT.

Friedmann PD, Dunn KE, Nunes EV, O'Brien CP.

J Subst Abuse Treat. 2018 Feb;85:31-33. doi: 10.1016/j.jsat.2017.11.008. Epub 2017 Nov 22. No abstract available.

PMID:
29273249
23.

Characterizing the subjective, observer-rated, and physiological effects of hydromorphone relative to heroin in a human laboratory study.

Dunn KE, Brands B, Marsh DC, Bigelow GE.

Psychopharmacology (Berl). 2018 Apr;235(4):971-981. doi: 10.1007/s00213-017-4814-3. Epub 2017 Dec 21.

24.

The relationship between treatment accessibility and preference amongst out-of-treatment individuals who engage in non-medical prescription opioid use.

Huhn AS, Tompkins DA, Dunn KE.

Drug Alcohol Depend. 2017 Nov 1;180:279-285. doi: 10.1016/j.drugalcdep.2017.08.019. Epub 2017 Sep 9.

25.

The risk for problematic opioid use in chronic pain: What can we learn from studies of pain and reward?

Finan PH, Remeniuk B, Dunn KE.

Prog Neuropsychopharmacol Biol Psychiatry. 2018 Dec 20;87(Pt B):255-262. doi: 10.1016/j.pnpbp.2017.07.029. Epub 2017 Aug 1. Review.

PMID:
28778406
26.

Frequency and correlates of sleep disturbance in methadone and buprenorphine-maintained patients.

Dunn KE, Finan PH, Andrew Tompkins D, Strain EC.

Addict Behav. 2018 Jan;76:8-14. doi: 10.1016/j.addbeh.2017.07.016. Epub 2017 Jul 14.

27.

Efficacy of Tramadol Extended-Release for Opioid Withdrawal: A Randomized Clinical Trial.

Dunn KE, Tompkins DA, Bigelow GE, Strain EC.

JAMA Psychiatry. 2017 Sep 1;74(9):885-893. doi: 10.1001/jamapsychiatry.2017.1838. Erratum in: JAMA Psychiatry. 2017 Sep 1;74(9):975. JAMA Psychiatry. 2018 Apr 1;75(4):409.

28.

Why aren't physicians prescribing more buprenorphine?

Huhn AS, Dunn KE.

J Subst Abuse Treat. 2017 Jul;78:1-7. doi: 10.1016/j.jsat.2017.04.005. Epub 2017 Apr 12.

29.

Precision Templated Bottom-Up Multiprotein Nanoassembly through Defined Click Chemistry Linkage to DNA.

Marth G, Hartley AM, Reddington SC, Sargisson LL, Parcollet M, Dunn KE, Jones DD, Stulz E.

ACS Nano. 2017 May 23;11(5):5003-5010. doi: 10.1021/acsnano.7b01711. Epub 2017 Apr 20.

30.

An experimental study of the putative mechanism of a synthetic autonomous rotary DNA nanomotor.

Dunn KE, Leake MC, Wollman AJ, Trefzer MA, Johnson S, Tyrrell AM.

R Soc Open Sci. 2017 Mar 22;4(3):160767. doi: 10.1098/rsos.160767. eCollection 2017 Mar.

31.

Randomized controlled trial of a computerized opioid overdose education intervention.

Dunn KE, Yepez-Laubach C, Nuzzo PA, Fingerhood M, Kelly A, Berman S, Bigelow GE.

Drug Alcohol Depend. 2017 Apr 1;173 Suppl 1:S39-S47. doi: 10.1016/j.drugalcdep.2016.12.003.

32.

Effects of incentives for naltrexone adherence on opiate abstinence in heroin-dependent adults.

Jarvis BP, Holtyn AF, DeFulio A, Dunn KE, Everly JJ, Leoutsakos JS, Umbricht A, Fingerhood M, Bigelow GE, Silverman K.

Addiction. 2017 May;112(5):830-837. doi: 10.1111/add.13724. Epub 2017 Feb 3.

33.

Behavioral risk assessment for infectious diseases (BRAID): Self-report instrument to assess injection and noninjection risk behaviors in substance users.

Dunn KE, Barrett FS, Herrmann ES, Plebani JG, Sigmon SC, Johnson MW.

Drug Alcohol Depend. 2016 Nov 1;168:69-75. doi: 10.1016/j.drugalcdep.2016.07.032. Epub 2016 Aug 25.

34.

A Phase 2, Double-Blind, Placebo-Controlled Randomized Trial Assessing the Efficacy of ABT-436, a Novel V1b Receptor Antagonist, for Alcohol Dependence.

Ryan ML, Falk DE, Fertig JB, Rendenbach-Mueller B, Katz DA, Tracy KA, Strain EC, Dunn KE, Kampman K, Mahoney E, Ciraulo DA, Sickles-Colaneri L, Ait-Daoud N, Johnson BA, Ransom J, Scott C, Koob GF, Litten RZ.

Neuropsychopharmacology. 2017 Apr;42(5):1012-1023. doi: 10.1038/npp.2016.214. Epub 2016 Sep 23.

35.

Opioid Overdose Experience, Risk Behaviors, and Knowledge in Drug Users from a Rural versus an Urban Setting.

Dunn KE, Barrett FS, Yepez-Laubach C, Meyer AC, Hruska BJ, Petrush K, Berman S, Sigmon SC, Fingerhood M, Bigelow GE.

J Subst Abuse Treat. 2016 Dec;71:1-7.

36.

Opioid Overdose History, Risk Behaviors, and Knowledge in Patients Taking Prescribed Opioids for Chronic Pain.

Dunn KE, Barrett FS, Fingerhood M, Bigelow GE.

Pain Med. 2017 Aug 1;18(8):1505-1515. doi: 10.1093/pm/pnw228.

37.

The electrophotonic silicon biosensor.

Juan-Colás J, Parkin A, Dunn KE, Scullion MG, Krauss TF, Johnson SD.

Nat Commun. 2016 Sep 14;7:12769. doi: 10.1038/ncomms12769.

38.

Continuous Abstinence During Early Alcohol Treatment is Significantly Associated with Positive Treatment Outcomes, Independent of Duration of Abstinence.

Dunn KE, Harrison JA, Leoutsakos JM, Han D, Strain EC.

Alcohol Alcohol. 2017 Jan;52(1):72-79. doi: 10.1093/alcalc/agw059. Epub 2016 Aug 27.

39.

Brief Opioid Overdose Knowledge (BOOK): A Questionnaire to Assess Overdose Knowledge in Individuals Who Use Illicit or Prescribed Opioids.

Dunn KE, Barrett FS, Yepez-Laubach C, Meyer AC, Hruska BJ, Sigmon SC, Fingerhood M, Bigelow GE.

J Addict Med. 2016 Sep-Oct;10(5):314-23. doi: 10.1097/ADM.0000000000000235.

40.

Investigating the dynamics of surface-immobilized DNA nanomachines.

Dunn KE, Trefzer MA, Johnson S, Tyrrell AM.

Sci Rep. 2016 Jul 8;6:29581. doi: 10.1038/srep29581.

41.

Assessing the potential of surface-immobilized molecular logic machines for integration with solid state technology.

Dunn KE, Trefzer MA, Johnson S, Tyrrell AM.

Biosystems. 2016 Aug;146:3-9. doi: 10.1016/j.biosystems.2016.05.006. Epub 2016 May 18.

PMID:
27208444
42.

Synergistic Biomineralization Phenomena Created by a Combinatorial Nacre Protein Model System.

Chang EP, Roncal-Herrero T, Morgan T, Dunn KE, Rao A, Kunitake JA, Lui S, Bilton M, Estroff LA, Kröger R, Johnson S, Cölfen H, Evans JS.

Biochemistry. 2016 Apr 26;55(16):2401-10. doi: 10.1021/acs.biochem.6b00163. Epub 2016 Apr 13.

43.

Comparison of methods to assess psychiatric medication adherence in methadone-maintained patients with co-occurring psychiatric disorder.

Dunn KE, King VL, Brooner RK.

Drug Alcohol Depend. 2016 Mar 1;160:212-7. doi: 10.1016/j.drugalcdep.2016.01.016. Epub 2016 Jan 30.

44.

Modelling DNA origami self-assembly at the domain level.

Dannenberg F, Dunn KE, Bath J, Kwiatkowska M, Turberfield AJ, Ouldridge TE.

J Chem Phys. 2015 Oct 28;143(16):165102. doi: 10.1063/1.4933426.

45.

Characterizing pain and associated coping strategies in methadone and buprenorphine-maintained patients.

Dunn KE, Finan PH, Tompkins DA, Fingerhood M, Strain EC.

Drug Alcohol Depend. 2015 Dec 1;157:143-9. doi: 10.1016/j.drugalcdep.2015.10.018. Epub 2015 Oct 19.

46.

Zonisamide Reduces Withdrawal Symptoms But Does Not Enhance Varenicline-Induced Smoking Cessation.

Dunn KE, Marcus TF, Kim C, Schroeder JR, Vandrey R, Umbricht A.

Nicotine Tob Res. 2016 May;18(5):1171-9. doi: 10.1093/ntr/ntv236. Epub 2015 Oct 17.

47.

Guiding the folding pathway of DNA origami.

Dunn KE, Dannenberg F, Ouldridge TE, Kwiatkowska M, Turberfield AJ, Bath J.

Nature. 2015 Sep 3;525(7567):82-6. doi: 10.1038/nature14860. Epub 2015 Aug 19.

48.

Arrhythmogenic Right Ventricular Cardiomyopathy: Toward a Modern Clinical and Genomic Understanding.

Dunn KE, Ashley EA.

Circ Cardiovasc Genet. 2015 Jun;8(3):421-4. doi: 10.1161/CIRCGENETICS.115.001119. No abstract available.

PMID:
26082552
49.

Characterizing opioid withdrawal during double-blind buprenorphine detoxification.

Dunn KE, Saulsgiver KA, Miller ME, Nuzzo PA, Sigmon SC.

Drug Alcohol Depend. 2015 Jun 1;151:47-55. doi: 10.1016/j.drugalcdep.2015.02.033. Epub 2015 Mar 12.

50.

Spontaneous reductions in smoking during double-blind buprenorphine detoxification.

Patrick ME, Dunn KE, Badger GJ, Heil SH, Higgins ST, Sigmon SC.

Addict Behav. 2014 Sep;39(9):1353-6. doi: 10.1016/j.addbeh.2014.04.023. Epub 2014 May 5.

Supplemental Content

Support Center